Willingness to pay for a dengue vaccine in Iran: Insights from a contingent valuation study. [PDF]
PLoS Negl Trop DisSoofi M +4 more
europepmc +1 more source
1-Year follow-up evaluation of TAK-003 dengue vaccine effectiveness against symptomatic disease and hospitalisation in adolescents during the 2024-2025 outbreak in São Paulo, Brazil: a test-negative case-control study. [PDF]
EClinicalMedicineKrug Mareto L +13 more
europepmc +1 more source
Efficacy, public health impact and optimal use of the Takeda dengue vaccine. [PDF]
Nat MedCracknell Daniels B +2 more
europepmc +2 more sources
Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data. [PDF]
Virol JKant R +5 more
europepmc +1 more source
T-Cell-Based Universal Dengue Vaccine Design for Robust Protective Response. [PDF]
Vaccines (Basel)Sun YF, Yeo Syin Lian A, Moi ML.
europepmc +1 more source
Dengue vaccine rollout in India: lessons for Pakistan's public health preparedness. [PDF]
Ann Med Surg (Lond)Sah S, Ahsan A, Tariq R, Yadav T.
europepmc +1 more source
Defining a Simplified Process in Yeast for Production of Enveloped VLP Dengue Vaccine. [PDF]
Bioengineering (Basel)de Sá Magalhães S +5 more
europepmc +1 more source
Dengue Vaccine Development and Deployment into Routine Immunization. [PDF]
Vaccines (Basel)Wilder-Smith A, Cherian T, Hombach J.
europepmc +1 more source
The Tolerability of the Dengue Vaccine TAK-003 (Qdenga<sup>®</sup>) in German Travelers: The Results of a Prospective Survey. [PDF]
Trop Med Infect DisJelinek T, Kramm J, Wagner M, Jelinek C.
europepmc +1 more source
Safety of the Dengue Vaccine TAK-003 and Factors Associated with Adverse Events in Travellers from Non-Endemic Areas: A Real-World Prospective Multicentre Pharmacovigilance Cohort Study in Spain. [PDF]
Lancet Reg Health EurCamprubí-Ferrer D +25 more
europepmc +1 more source